{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:05:55Z","timestamp":1784531155932,"version":"3.55.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119697","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:11:50Z","timestamp":1782911510000},"page":"119697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CAR-T cell therapy and oncolytic viruses: A synergic approach for advanced GI cancers"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8165-1344","authenticated-orcid":false,"given":"Seyed Kiarash","family":"Aghayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9633-4678","authenticated-orcid":false,"given":"Amin","family":"Azizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-2295","authenticated-orcid":false,"given":"Hadi","family":"Esmaeili Gouvarchin Ghaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-2126","authenticated-orcid":false,"given":"Ebrahim","family":"Salimi-Sabour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7297-3085","authenticated-orcid":false,"given":"Reza","family":"Mirnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Vazifedust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-0991","authenticated-orcid":false,"given":"Mohamadali","family":"Abyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5257-9004","authenticated-orcid":false,"given":"Vahid","family":"Nazarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119697_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.942035","article-title":"Global burden of major gastrointestinal cancers and its association with socioeconomics, 1990-2019","volume":"12","author":"Hong","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119697_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4346576","article-title":"Immunotherapy in gastrointestinal cancers","volume":"2017","author":"Procaccio","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2026.119697_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-031-61238-1_14","article-title":"Immunotherapy in gastrointestinal cancers","volume":"192","author":"Lote","year":"2024","journal-title":"Cancer Treat. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12943-023-01770-6","article-title":"Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119697_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031071","article-title":"Radiation and immunotherapy in upper gastrointestinal cancers: the current state of play","volume":"22","author":"Donlon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.biopha.2026.119697_bib6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/jama.2025.10218","article-title":"Early-onset gastrointestinal cancers: a review","volume":"334","author":"Jayakrishnan","year":"2025","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.biopha.2026.119697_bib7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2174\/156800911796191060","article-title":"Molecular targeted therapy of gastrointestinal cancer","volume":"11","author":"Wiedmann","year":"2011","journal-title":"Curr. Cancer Drug. Targets"},{"issue":"4","key":"10.1016\/j.biopha.2026.119697_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119697_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41568-018-0006-7","article-title":"A history of exploring cancer in context","volume":"18","author":"Maman","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119697_bib11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/advances\/nmab132","article-title":"Current evidence and directions for intermittent fasting during cancer chemotherapy","volume":"13","author":"Gabel","year":"2022","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.biopha.2026.119697_bib12","series-title":"StatPearls","article-title":"Cancer Chemotherapy","author":"Amjad","year":"2025"},{"issue":"3","key":"10.1016\/j.biopha.2026.119697_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"7","key":"10.1016\/j.biopha.2026.119697_bib14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.trecan.2019.05.010","article-title":"Integrative approaches to cancer immunotherapy","volume":"5","author":"Szeto","year":"2019","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119697_bib15","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR\u2011T cell therapy: a breakthrough in traditional cancer treatment strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1186\/s12885-020-07180-x","article-title":"Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice","volume":"20","author":"Li","year":"2020","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2026.119697_bib17","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119697_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109256","article-title":"Development of chimeric antigen receptor (CAR)-T cells targeting A56 viral protein implanted by oncolytic virus","volume":"27","author":"Cho","year":"2024","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.biopha.2026.119697_bib19","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119697_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.biopha.2026.119697_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"5","key":"10.1016\/j.biopha.2026.119697_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050674","article-title":"CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-023-01714-0","article-title":"Regulatory cells and the effect of cancer immunotherapy","volume":"22","author":"Iglesias-Escudero","year":"2023","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2026.119697_bib24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119697_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-024-03817-z","article-title":"Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells","volume":"74","author":"Khaliulin","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"37","key":"10.1016\/j.biopha.2026.119697_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/EDBK_180328","article-title":"Adoptive T-cell therapy for solid tumors","author":"Yeku","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell. Res. Ther."},{"issue":"25","key":"10.1016\/j.biopha.2026.119697_bib29","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.119697_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric antigen receptor T cells targeting integrin \u03b1v\u03b26 expressed on cholangiocarcinoma cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front. Oncol."},{"issue":"14","key":"10.1016\/j.biopha.2026.119697_bib31","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-08-0543","article-title":"Endothelin B receptor, a new target in cancer immune therapy","volume":"15","author":"Kandalaft","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119697_bib32","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1172\/JCI58814","article-title":"IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors","volume":"121","author":"Kerkar","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"20","key":"10.1016\/j.biopha.2026.119697_bib33","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119697_bib34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib35","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1038\/s41598-019-43668-8","article-title":"A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma","volume":"9","author":"Sakhawat","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.biopha.2026.119697_bib36","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.biopha.2026.119697_bib37","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","article-title":"Recent advances of oncolytic virus in cancer therapy","volume":"16","author":"Mondal","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.biopha.2026.119697_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2019.197675","article-title":"Recent advances in oncolytic virus-based cancer therapy","volume":"270","author":"Fu","year":"2019","journal-title":"Virus Res."},{"key":"10.1016\/j.biopha.2026.119697_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1375433","article-title":"New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy","volume":"15","author":"Chowaniec","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119697_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1012806","article-title":"Immunovirotherapy: the role of antibody based therapeutics combination with oncolytic viruses","volume":"13","author":"Jafari","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119697_bib41","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119697_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455163","article-title":"Oncolytic virus and CAR-T cell therapy in solid tumors","volume":"15","author":"Ponterio","year":"2024","journal-title":"Front. Immunol."},{"issue":"3-4","key":"10.1016\/j.biopha.2026.119697_bib43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/hum.2020.278","article-title":"Combining oncolytic viruses with chimeric antigen receptor T cell therapy","volume":"32","author":"McGrath","year":"2021","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119697_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2026.119697_bib45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00262-024-03757-8","article-title":"Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.biopha.2026.119697_bib46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biopha.2026.119697_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108882","article-title":"Oncolytic virus delivery modulated immune responses toward cancer therapy: challenges and perspectives","volume":"108","author":"Keshavarz","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119697_bib48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cytogfr.2020.07.005","article-title":"Engineering and combining oncolytic measles virus for cancer therapy","volume":"56","author":"Leber","year":"2020","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.biopha.2026.119697_bib49","article-title":"Regulation of viral replication by host restriction factors","volume":"16","author":"Lin","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib50","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12935-022-02585-z","article-title":"Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction","volume":"22","author":"Mardi","year":"2022","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.biopha.2026.119697_bib51","article-title":"Regulation of ubiquitination in sepsis: from PAMP versus DAMP to peripheral inflammation and cell death","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119697_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115149","article-title":"Mechanistic insights into PAMP and DAMP driven activation of NETosis in autoimmune disorders","volume":"162","author":"Bhatia","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119697_bib53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev-pathmechdis-012419-032847","article-title":"DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation","volume":"15","author":"Zindel","year":"2020","journal-title":"Annu. Rev. Pathol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119697_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/v15081645","article-title":"Oncolytic virus engineering and utilizations: cancer immunotherapy perspective","volume":"15","author":"Muthukutty","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","article-title":"Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects","volume":"9","author":"Fu","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119697_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/humc.2016.031","article-title":"Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent\/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma","volume":"27","author":"Patel","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib57","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/s41598-017-02503-8","article-title":"Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119697_bib58","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/mt.2009.205","article-title":"Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL","volume":"18","author":"Huang","year":"2010","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119697_bib59","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41587-023-02118-7","article-title":"An oncolytic virus-T cell chimera for cancer immunotherapy","volume":"42","author":"Chen","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"19","key":"10.1016\/j.biopha.2026.119697_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910522","article-title":"Concepts in oncolytic adenovirus therapy","volume":"22","author":"Mantwill","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119697_bib61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.soc.2019.02.007","article-title":"Oncolytic immunotherapy","volume":"28","author":"Hennessy","year":"2019","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"2","key":"10.1016\/j.biopha.2026.119697_bib62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/14712598.2020.1811848","article-title":"Combining oncolytic virus with FDA approved pharmacological agents for cancer therapy","volume":"21","author":"Zhang","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119697_bib63","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41571-024-00977-w","article-title":"Treatment advances across the cervical cancer spectrum","volume":"22","author":"Francoeur","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119697_bib64","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00277-023-05488-9","article-title":"Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies","volume":"103","author":"Gao","year":"2024","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119697_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051106","article-title":"Parking CAR T cells in tumours: oncolytic viruses as valets or vandals?","volume":"13","author":"Evgin","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.biopha.2026.119697_bib66","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119697_bib67","doi-asserted-by":"crossref","DOI":"10.4161\/21505594.2014.988098","article-title":"Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors","volume":"4","author":"Nishio","year":"2015","journal-title":"Oncoimmunology"},{"issue":"559","key":"10.1016\/j.biopha.2026.119697_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.biopha.2026.119697_bib69","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","article-title":"Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma","volume":"70","author":"Huang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.biopha.2026.119697_bib70","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00262-021-02895-7","article-title":"Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40\/4-1BB using oncolytic viral gene therapy","volume":"70","author":"Wenthe","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2026.119697_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2025.105026","article-title":"Exploring novel strategies of oncolytic viruses and gut microbiota to enhance CAR-T cell therapy for colorectal cancer","volume":"417","author":"Yi","year":"2025","journal-title":"Cell. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119697_bib72","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.119697_bib73","article-title":"Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib74","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s42003-021-01914-8","article-title":"Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors","volume":"4","author":"Rosewell Shaw","year":"2021","journal-title":"Commun. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119697_bib75","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00262-025-04039-7","article-title":"Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression","volume":"74","author":"Aboalela","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib76","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41420-023-01626-4","article-title":"Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-\u03b3 promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors","volume":"9","author":"Fang","year":"2023","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.biopha.2026.119697_bib77","article-title":"A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTE(FAP5\/CD3), CAR-T cells, and immunotoxins in hepatocellular carcinoma","volume":"16","author":"Dong","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib78","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.biopha.2026.119697_bib79","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119697_bib80","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jcyt.2019.01.003","article-title":"Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods","volume":"21","author":"Harrison","year":"2019","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.biopha.2026.119697_bib81","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119697_bib82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12185-016-2031-1","article-title":"Gene and virotherapy for hematological malignancies","volume":"104","author":"Domingo-Musibay","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119697_bib83","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119697_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.14","article-title":"Chimeric antigen receptor-engineered T cells as oncolytic virus carriers","volume":"2","author":"VanSeggelen","year":"2015","journal-title":"Mol. Ther. Oncolytics"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600733X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600733X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:39:45Z","timestamp":1784529585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222600733X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":84,"alternative-id":["S075333222600733X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119697","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy and oncolytic viruses: A synergic approach for advanced GI cancers","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119697"}}